Tarik Skubal has built the kind of résumé that usually sends teams sprinting to the front of the line.
Since July of 2023, the left-hander has been a force: a 2.47 ERA across 626.1 innings, supported by a 2.70 xERA, a 2.42 FIP, and a 26.7% K-BB%, all of it good for 21.3 fWAR. Those marks lead baseball over that stretch, and not by a small margin.
He’s also stacked up the hardware - two Cy Youngs in 2024 and 2025, a pitcher Triple Crown in 2024, and a record-breaking $32M in his final arbitration-eligible season in 2026. At 29, and now entering free agency without draft-pick compensation after being traded at midseason from Detroit to LA, he’s positioned for a monster deal.
That’s exactly why the market is expected to go wild. Skubal could end up as the most valuable free agent pitcher of the 2000s, maybe even all time.
Gerrit Cole had a better platform year in 2019, but he hadn’t been this dominant over a longer span. Yoshinobu Yamamoto was younger, but he was unproven in the majors.
David Price had a longer record of being very good, but not as long a run at this level. Max Scherzer had a similar shape to his career, though he hadn’t hit Skubal’s peak.
Clayton Kershaw and Stephen Strasburg never got there in free agency. CC Sabathia may have the strongest case, but comparing pitchers across eras is messy, especially with how much the game has changed over the last 10 to 15 years.
It’s no surprise Skubal is projected to land somewhere in the $350M to 500M range.
And yet, the Mets probably shouldn’t be the team making that call.
The first issue is health. Skubal missed the first half of 2023 while recovering from flexor tendon surgery he had in August of 2022.
Then in 2026, he had another procedure, this time to remove loose bodies from his left elbow. He did bounce back quickly, but that still means two left-elbow operations in four years, plus the Tommy John surgery he had in college in 2016.
The average shelf life of a TJS is somewhere between 5 and 10 years, and Skubal is now on the back end of that window. That’s a lot of warning lights for any pitcher, and more than usual for one this expensive.
There’s also the broader history of pitchers like him. High-end starters entering their 30s do not age especially well as a group.
Even pitchers who had already piled up more than 20 fWAR before turning 30 - Skubal has 24.7 career fWAR - have averaged just 10.8 fWAR after that point. The picture barely improves when the bar gets raised to pitchers with 30, 40, or 50 fWAR before age 30.
There are obvious exceptions. Justin Verlander has been brilliant well into his 30s and 40s.
Max Scherzer did it for much of the last decade. Chris Sale is still going.
Zack Greinke nearly matched his pre-30 production after turning 30, and Roy Halladay actually exceeded what he did before that age. But the other side of the ledger is heavy: Felix Hernandez was basically finished at 30.
So were Ben Sheets, Madison Bumgarner, Stephen Strasburg, Brandon Webb, Matt Cain, and Tim Lincecum. Roy Oswalt, Jake Peavy, Johnny Cueto, and David Price were merely okay after 30, and that’s about the middle of the road for this kind of pitcher.
Time and injury risk win more often than not.
That said, the comparison is not perfect. This is a blunt way to look at aging curves, and more detailed age splits or deeper metrics would sharpen the picture.
There’s also a built-in feature of this player type: they’re usually either excellent or unavailable. That’s different from a healthy but mediocre starter who just takes up innings and blocks roster flexibility.
In that sense, the downside is at least clean.
Still, the question remains whether it makes sense to hand a pitcher with that profile more than $350M when the median and mean outcome from similar players suggests roughly 15 wins the rest of the way. That works out to more than $20M per win, using a very rough shorthand, and that’s before accounting for the injury risk baked into the deal.
The Mets’ broader financial picture makes the fit even trickier. The league’s current CBA proposals include a cap-and-floor system, with a proposed cap of $245.3M. The Mets’ 2026 payroll was $346.7M, more than $100M above that figure, and with Bo Bichette opting in, none of the major money comes off the books until next offseason.
A hard cap is still highly unlikely, but the direction of the talks points toward harsher penalties for the biggest spenders, probably draft-pick based. That matters for a team already committing nearly $100M per year to Juan Soto and Francisco Lindor for the next five years, while still having other roster holes to fill. Adding another top-of-the-market contract on top of that would be a massive squeeze, if not an outright impossibility.
Skubal would be a huge addition. He’d make the 2027 Mets better, and he’d absolutely help their World Series odds. But when you stack the elbow history, the aging risk, and the payroll and CBA concerns together, this looks like the kind of opportunity the Mets should let someone else chase.
In Other News...
Mets Just Sent A Strong Signal With An Unusual Infield Move
The Mets added another infield option this week, signing Christian Cairo to a one-year split contract after claiming him off waivers from the Phillies. Cairo spent most of the 2026 season at Triple-A with Philadelphia before ending the year at Syracuse, giving New York a player it has already seen up close in its own system and a bit more organizational depth in the middle of the diamond.
It also came as part of a broader roster shuffle, with the Mets outrighting several players from the 40-man roster, including Cristian Pache, Eric Wagaman, Philip Abner, and Cameron Weston. Moves like this often say as much about the clubs winter priorities as any splashier transaction, and New York is clearly continuing to sort through which pieces it wants to keep in the mix as the roster takes shape. [Read more 🡒]
Mets Prospects Are Sending Very Different Signals In Arizona
The Arizona Fall League has offered a mixed read on the Mets prospects this week, with Surprise cycling through a stretch of games that has produced both encouraging individual performances and some uneven team results. From Oct. 27 through Oct. 31, the box scores have given a little of everything, as Bruin Agbayani, Boston Baro, Cole Mathis, Irving Cota, Brendan Girton, Ryan Lambert, Peyton Prescott and Calvin Ziegler all turned in recent action worth tracking for a farm system trying to sort out who is trending up.
For the Mets, the bigger takeaway is not any single score but the range of signals coming from Arizona. Some players have added to solid cumulative numbers, while others are still working through the kind of up-and-down stretch that often defines fall ball, leaving the organization with a fuller picture but not a finished one. The results have been useful, if not always tidy, and they have kept several of these names in the conversation as the AFL schedule moves along. [Read more 🡒]
Mets Add Another Pitching Wild Card To Their 40-Man Mix
The Mets added another arm to their 40-man mix by claiming right-hander Jack Anderson off waivers from the Twins, a move that fits the clubs recent habit of collecting pitchers who can cover multiple roles. Anderson has already seen big league time with Minnesota and Boston, and his brief major league sample last year came with a 2.19 ERA, enough to make him an intriguing depth piece as the roster takes shape.
Anderson also arrives with two minor league options remaining, which gives the Mets some flexibility if they want to shuttle him between New York and Syracuse as needed. For now, he looks like the kind of pitcher who could be deployed as an opener or a long reliever, a useful profile for a staff that always seems to need one more option ready to absorb innings when the schedule gets messy. [Read more 🡒]